中国中老年人群新型肥胖指数的范围、时间趋势及影响因素:来自一项全国代表性纵向研究的见解
Ranges, temporal trend, and determinants of novel obesity indices in middle-aged and older Chinese population: insights from a nationally representative and longitudinal study.
作者信息
Huang Liufang, Zhou Yifan, Abuduxukuer Kaiweisa, Wang Chuchu, Hou Ya'nan, Shi Wenming, Luo Jianfeng, Wei Jin, Yue Yuhang
机构信息
Division of Pediatric Gastroenterology and Nutrition, Xinhua Hospital Affiliated to Shanghai Jiao Tong University School of Medicine, Shanghai, China.
Department of Ophthalmology, Shanghai Tenth People's Hospital, School of Medicine, Tongji University, Shanghai, China.
出版信息
Front Public Health. 2025 Aug 14;13:1571254. doi: 10.3389/fpubh.2025.1571254. eCollection 2025.
BACKGROUND
Traditional obesity assessment using body mass index (BMI) fails to adequately capture fat distribution, particularly central obesity, which is closely linked to metabolic dysfunction and obesity-related complications. Alternative obesity indices that better reflecting fat distribution and body composition have shown promise, yet large-scale population-based data remain limited. This study evaluates the ranges, temporal trends, and associated factors of novel obesity indexes in a nationally representative cohort of middle-aged and older Chinese adults.
METHODS
Using data from the China Health and Retirement Longitudinal Study (CHARLS), we analyzed 17,708 adults in 2011 and followed 5,078 participants over 5 years nationally. Six obesity indexes: waist-to-height ratio (WHtR), lipid accumulation product (LAP), visceral adiposity index (VAI), body shape index (ABSI), Chinese visceral adiposity index (CVAI), and weight-adjusted waist index (WWI), were evaluated for ranges, temporal trends, and associated factors using logistic regression and generalized estimating equations (GEE). Associated factors included demographic, socioeconomic, lifestyle, and medical variables.
RESULTS
The national ranges were as follows: VAI (-1.805 to 6.615), ABSI (0.071 to 0.095), WHtR (0.462 to 0.622), CVAI (48.993 to 147.057), WWI (10.264 to 12.144), and LAP (-3.158 to 80.818). Significant associated factors were grouped into demographic (age, sex, urban/rural residence), medical (diabetes, and hypertension), and lifestyle factors (smoking, and drinking), with varying impacts across indexes. Over the five-year period, WHtR, CVAI, and LAP increased significantly ( = 0.00489, = 4.51607, = 6.37441; all < 0.001), while ABSI decreased ( = -0.00048, < 0.001). Interaction effects showed that diabetic participants experienced reductions in VAI, WHtR, CVAI, and LAP, indication a time-dependent change. In contrast, chronic kidney disease (CKD) and hypertension had stable effects on obesity indices, with no significant changes over time.
CONCLUSION
This study provides nationally representative baseline ranges, temporal changes and influencing factors of novel obesity indexes among middle-aged and older Chinese adults. These findings underscore the potential of these obesity indices to guide clinical interventions aimed at controlling and preventing obesity-related health issues.
背景
使用体重指数(BMI)进行传统的肥胖评估无法充分反映脂肪分布情况,尤其是中心性肥胖,而中心性肥胖与代谢功能障碍及肥胖相关并发症密切相关。能够更好反映脂肪分布和身体成分的替代肥胖指数已显示出应用前景,但基于大规模人群的数据仍然有限。本研究评估了具有全国代表性的中国中老年成年人队列中新型肥胖指数的范围、时间趋势及相关因素。
方法
利用中国健康与养老追踪调查(CHARLS)的数据,我们分析了2011年的17708名成年人,并在全国范围内对5078名参与者进行了为期5年的随访。使用逻辑回归和广义估计方程(GEE)对六个肥胖指数:腰高比(WHtR)、脂质蓄积产物(LAP)、内脏脂肪指数(VAI)、体型指数(ABSI)、中国内脏脂肪指数(CVAI)和体重校正腰围指数(WWI)的范围、时间趋势及相关因素进行了评估。相关因素包括人口统计学、社会经济、生活方式和医学变量。
结果
全国范围如下:VAI(-1.805至6.615)、ABSI(0.071至0.095)、WHtR(0.462至0.622)、CVAI(48.993至147.057)、WWI(10.264至12.144)和LAP(-3.158至80.818)。显著相关因素分为人口统计学因素(年龄、性别、城乡居住情况)、医学因素(糖尿病和高血压)和生活方式因素(吸烟和饮酒),各指数受到的影响各不相同。在这五年期间,WHtR、CVAI和LAP显著增加(β = 0.00489,β = 4.51607,β = 6.37441;P均<0.001),而ABSI下降(β = -0.00048,P<0.001)。交互作用表明,糖尿病参与者的VAI、WHtR、CVAI和LAP降低,表明存在时间依赖性变化。相比之下,慢性肾脏病(CKD)和高血压对肥胖指数有稳定影响,随时间无显著变化。
结论
本研究提供了具有全国代表性的中国中老年成年人新型肥胖指数的基线范围、时间变化及影响因素。这些发现强调了这些肥胖指数在指导旨在控制和预防肥胖相关健康问题的临床干预方面的潜力。
相似文献
Int J Cardiol Cardiovasc Risk Prev. 2025-7-1
Zhonghua Gan Zang Bing Za Zhi. 2025-8-20
本文引用的文献
Diabetol Metab Syndr. 2024-9-14
Lancet Diabetes Endocrinol. 2024-8
Nat Rev Endocrinol. 2024-11